Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 12;10(1):1886726.
doi: 10.1080/2162402X.2021.1886726.

Expand to shield: IL-15 and in situ lymphocytic proliferation

Affiliations
Review

Expand to shield: IL-15 and in situ lymphocytic proliferation

Gabriela Bindea et al. Oncoimmunology. .

Abstract

The tumor microenvironment includes a complex network of cytokines and chemokines that contribute to shaping the intratumoral immune reaction. Understanding the mechanisms leading to immune-hot (Immunoscore-high) altered (excluded and immunosuppressed) and cold tumors are of critical importance for successful anti-cancer therapies. Two essential mechanisms are highlighted. Specific chemokines and adhesion molecules appeared to target and attract immune effector T cells to the tumor microenvironment and to specific regions within the tumor. These mechanisms are dependent upon intratumoral IL-15 expression. Decreased IL15 expression also affected the local proliferation of B and T lymphocytes. A comprehensive analysis revealed a major contribution of IL15 in shaping the tumor immune contexture. Thus, an in situ lymphocytic infiltration is mediated through chemokines and attraction inside or around the tumor microenvironment, and an IL15-mediated in situ lymphocytic proliferation, which expand the local pool of intratumoral cytotoxic CD8 T-cells are key determinants of the immune contexture. Increased IL15 expression and local proliferation of T-cells were associated with decreased risk of tumor recurrence and prolonged survival of cancer patients. These data provide further mechanisms to prioritize research and help in designing better therapeutic interventions.

Keywords: IL-15; T-cells; attraction; chemokine; chromosomal instability; colorectal cancer; immunity; immunoscore; prognosis; proliferation; survival; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Intrametastatic immune landscape. (a) an in situ lymphocytic infiltration is mediated through chemokines and attraction inside or around the tumor microenvironment. IL15, produced mainly by activated myeloid cells and tumor cells, activates cytotoxic CD8 T-cells and NK-cells, which together with Th1 cells produce IFNG, a major cytokine involved together with XCL1 in shaping a good immune contexture and in activating cDC1 cells. These activated cDC1 cells, by producing chemokines such as CXCL9/10 are attracting CXCR3+ cells, notably memory CD45RO+ T-cells, cytotoxic CD8 T-cells and NK-cells. (b) In parallel, IL15 is also inducing a direct in situ lymphocytic proliferation, which expand the local pool of intratumoral cytotoxic CD8 T-cells. IL15 and these proliferating CD8 T-cells were associated with prolonged survival in cancer patients

Similar articles

Cited by

References

    1. Galon J, Bruni D.. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–3. doi:10.1016/j.immuni.2019.12.018. PMID: 31940273. - DOI - PubMed
    1. Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. doi:10.1038/s41568-020-0285-7. PMID: 32753728. - DOI - PubMed
    1. Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. doi:10.1007/s00281-011-0264-x. PMID: 21461991. - DOI - PMC - PubMed
    1. Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. PMID: 27650038. - DOI - PMC - PubMed
    1. Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. PMID: 27121213. - DOI - PMC - PubMed

Publication types

LinkOut - more resources